News Conference News ACC 2025 DETECT-AS: Alert System Increases AV Replacement in Eligible Patients Michael O'Riordan April 04, 2025
News Conference News ACC 2025 By 2 Years, Tricuspid TEER Reduces Hospitalizations for HF: TRILUMINATE Michael O'Riordan March 31, 2025
News Conference News ACC 2025 Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection Michael O'Riordan March 30, 2025
News Opinion Editor's Corner ACC 2025 What’s Going to Be Hot at ACC 2025? Michael O'Riordan March 26, 2025
News Conference News ACC 2023 Studies Support (Careful) Return to Sport for Athletes With Genetic Conditions Michael O'Riordan March 07, 2023
News Conference News ACC 2022 Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years Michael O'Riordan April 04, 2022
News Conference News ACC 2022 What’s Going to Be Hot at ACC 2022, In Person or Virtual Shelley Wood March 28, 2022
News Conference News ACC 2021 Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC Michael O'Riordan May 17, 2021
News Conference News ACC 2020 New Patient-Focused TAVR Quality Score Rolling Out to US Hospitals Michael O'Riordan April 06, 2020
News Conference News ACC 2020 Early Data Support TAVR in Bicuspid Valves, but Questions Remain Michael O'Riordan March 29, 2020
News Conference News ACC 2020 Lower Risk of Death With Conscious Sedation in TAVR: TVT Registry Michael O'Riordan March 19, 2020
News Conference News ACC 2019 My Takeaways From ACC 2019: Breaking With Embargoes? Despite the Drama, Embargoes Set to Stay Shelley Wood April 05, 2019
News Conference News ACC 2019 Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery Michael O'Riordan March 17, 2019
News Conference News ACC 2017 Simplified MRI Imaging Tests May Help ID Kids at High CV Risk During Sports Michael O'Riordan March 24, 2017
News Conference News ACC 2017 Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery Michael O'Riordan March 19, 2017
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017